What is Journey Colab?
Journey Colab is at the forefront of innovation in the pharmaceutical sector, specifically targeting the critical need for effective addiction treatments. The company's mission is to harness the scientific potential of psychedelic compounds to offer durable remission for individuals battling addiction. By establishing a network of Centers of Excellence, Journey Colab integrates cutting-edge research with comprehensive care models. Their strategic focus addresses the persistent gap in current addiction therapies, particularly for alcohol-related disorders, by advocating for a holistic approach that combines pharmacotherapy with psychotherapy and robust community support. The company is committed to enhancing accessibility to these treatments, with a strong emphasis on equity and collaborative partnerships, including engagement with Indigenous communities.
How much funding has Journey Colab raised?
Journey Colab has raised a total of $15M across 2 funding rounds:
Angel/Seed
$3M
Series A
$12M
Angel/Seed (2020): $3M with participation from Apollo Projects
Series A (2021): $12M led by Uprising, Delphi VC, MBX Capital, and Lionheart Ventures
Key Investors in Journey Colab
Delphi VC
Delphi VC is an investment firm that focuses on companies with the potential to significantly impact the world, often investing in early-stage ventures and actively collaborating with their founding teams.
MBX Capital
MBX Capital is a venture capital firm specializing in healthcare and biotechnology companies that challenge conventional approaches to public health, with a focus on early-stage companies innovating in overlooked areas.
Lionheart Ventures
Lionheart Ventures Co operates within the lending and brokerage industry, focusing on providing capital and strategic support to companies.
What's next for Journey Colab?
The recent major strategic investment signals a pivotal growth phase for Journey Colab, positioning it for accelerated development and market penetration. This capital infusion is expected to fuel the expansion of its research initiatives, enhance its clinical trial capabilities, and potentially broaden its therapeutic pipeline. As Journey Colab continues to scale its operations, its focus will likely remain on solidifying its position as a leader in psychedelic therapy for addiction, navigating regulatory pathways, and forging strategic alliances to ensure widespread patient access. The company's trajectory suggests a strong emphasis on translating scientific breakthroughs into tangible clinical solutions, aiming to redefine the landscape of addiction treatment.
See full Journey Colab company page
